艾滋病毒 1 型感染者延迟诊断和治疗对预期寿命的影响:英国协作艾滋病毒队列(英国 CHIC)研究。

Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.

机构信息

School of Social and Community Medicine, Bristol University, Bristol BS8 2PS, UK.

出版信息

BMJ. 2011 Oct 11;343:d6016. doi: 10.1136/bmj.d6016.

Abstract

OBJECTIVES

To estimate life expectancy for people with HIV undergoing treatment compared with life expectancy in the general population and to assess the impact on life expectancy of late treatment, defined as CD4 count <200 cells/mm(3) at start of antiretroviral therapy.

DESIGN

Cohort study.

SETTING

Outpatient HIV clinics throughout the United Kingdom. Population Adult patients from the UK Collaborative HIV Cohort (UK CHIC) Study with CD4 count ≤ 350 cells/mm(3) at start of antiretroviral therapy in 1996-2008.

MAIN OUTCOME MEASURES

Life expectancy at the exact age of 20 (the average additional years that will be lived by a person after age 20), according to the cross sectional age specific mortality rates during the study period.

RESULTS

1248 of 17,661 eligible patients died during 91,203 person years' follow-up. Life expectancy (standard error) at exact age 20 increased from 30.0 (1.2) to 45.8 (1.7) years from 1996-9 to 2006-8. Life expectancy was 39.5 (0.45) for male patients and 50.2 (0.45) years for female patients compared with 57.8 and 61.6 years for men and women in the general population (1996-2006). Starting antiretroviral therapy later than guidelines suggest resulted in up to 15 years' loss of life: at age 20, life expectancy was 37.9 (1.3), 41.0 (2.2), and 53.4 (1.2) years in those starting antiretroviral therapy with CD4 count <100, 100-199, and 200-350 cells/mm(3), respectively.

CONCLUSIONS

Life expectancy in people treated for HIV infection has increased by over 15 years during 1996-2008, but is still about 13 years less than that of the UK population. The higher life expectancy in women is magnified in those with HIV. Earlier diagnosis and subsequent timely treatment with antiretroviral therapy might increase life expectancy.

摘要

目的

评估接受治疗的 HIV 感染者与普通人群相比的预期寿命,并评估延迟治疗(定义为开始抗逆转录病毒治疗时 CD4 计数<200 个细胞/mm³)对预期寿命的影响。

设计

队列研究。

地点

英国各地的门诊 HIV 诊所。人群:来自英国协作性 HIV 队列研究(UK CHIC)的成年患者,1996-2008 年期间开始抗逆转录病毒治疗时 CD4 计数≤350 个细胞/mm³。

主要观察指标

根据研究期间的横断面年龄特异性死亡率,在 20 岁时的预期寿命(一个人在 20 岁以后将多活的精确年数)。

结果

在 91203 人年的随访中,17661 名符合条件的患者中有 1248 人死亡。从 1996-9 年到 2006-8 年,20 岁时的预期寿命(标准误差)从 30.0(1.2)岁增加到 45.8(1.7)岁。男性患者的预期寿命为 39.5(0.45)岁,女性患者的预期寿命为 50.2(0.45)岁,而普通人群(1996-2006 年)的男性和女性的预期寿命分别为 57.8 和 61.6 岁。延迟到指南建议的时间开始抗逆转录病毒治疗会导致长达 15 年的生命损失:在 20 岁时,CD4 计数<100、100-199 和 200-350 个细胞/mm³的患者开始抗逆转录病毒治疗时的预期寿命分别为 37.9(1.3)、41.0(2.2)和 53.4(1.2)岁。

结论

1996-2008 年期间,接受 HIV 感染治疗的患者的预期寿命增加了 15 年以上,但仍比英国人口少约 13 年。在 HIV 患者中,女性的更高预期寿命更加明显。早期诊断和随后及时进行抗逆转录病毒治疗可能会增加预期寿命。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bfc/4788290/5804431fdd64/maym857151.f1_default.jpg

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索